ArticleBritish journal of cancer1995
Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients.
Article in British journal of cancer, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- A systematic review of humoral immune responses against tumor antigens.Cancer immunology, immunotherapy : CII · 2009Pooled it
- Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].Breast cancer research : BCR · 2006Trial
- A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer.Cancer immunology, immunotherapy : CII · 2004Trial
- Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.The Journal of clinical investigation · 1997Trial
- The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges.Biomedicines · 2022Review
- Autoantibodies in Early Detection of Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Article
- Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.International journal of cancer · 2018Article
- Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.BioMed research international · 2017Article
- IgE immunotherapy against cancer.Current topics in microbiology and immunology · 2015Review
- Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.Cancer causes & control : CCC · 2013Article
- Natural and Induced Humoral Responses to MUC1.Cancers · 2011Article
- Correlates of the preoperative level of CA125 at presentation of ovarian cancer.Gynecologic oncology · 2010Article
- CA125 immune complexes in ovarian cancer patients with low CA125 concentrations.Clinical chemistry · 2010Article
- Genomic and proteomic biomarkers for cancer: a multitude of opportunities.Biochimica et biophysica acta · 2009Review
- Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1).Journal of experimental & clinical cancer research : CR · 2009Article
- Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Article
- Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma.BMC gastroenterology · 2006Article
- Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors.Clinical & experimental metastasis · 2003Article
- MUC1 and the immunobiology of cancer.Journal of mammary gland biology and neoplasia · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating immune complexes (CICs) containing polymorphic epithelial mucin (PEM/MUC-1) were found in sera of 24.5% of 151 primary breast carcinoma patients and 18-21.4% of patients with advanced ovarian (n = 56) and breast carcinomas (n = 61), 37% of patients with benign breast tumours, but in only 2.1% of 96 healthy individuals. The incorporation of PEM into CICs affects the detection of circulating PEM in commercial immunoassays such as the CA 15-3 assay, as suggested by a negative correlation between levels of PEM-containing immune complexes (PEM-CICs) and CA 15-3 values, and confirmed by isolation of PEM from CA 15-3-negative sera containing high levels of PEM-CICs. The amounts of PEM masked by human antibodies correspond to significant values of the CA 15-3 assay when monitoring patients for carcinoma. Most antibodies in PEM-CICs were of IgG class, suggesting their specific nature to the PEM epitopes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.